Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Marta Pratcorona, Montserrat Torrebadell, Neus Villamor, Maria Rozman, Mireia Camós, Ana Carrió, Dolors Costa, Marina Díaz Beyáa, Emili Montserrat, Jordi Esteve

Blood (2009) 114 (22): 2611.

https://doi.org/10.1182/blood.V114.22.2611.2611

Published: 2009

Journal Articles

Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.

Rita Coutinho, MD, Dolors Costa, PhD, Ana Carrió, PhD, Ana Vidal, BS, Mohammed Belkaid, MS, Elias Campo, MD, PhD, Emili Montserrat, MD, PhD, Benet Nomdedeu, MD

Blood (2009) 114 (22): 1746.

https://doi.org/10.1182/blood.V114.22.1746.1746

Published: 2009

Journal Articles

Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics

Marta Pratcorona, Mireia Camós, Montserrat Torrebadell, Maria Rozman, Ana Carrió, Dolors Costa, Alexandra Valera, Elias Campo, Emili Montserrat, Jordi Esteve

Blood (2008) 112 (11): 2522.

https://doi.org/10.1182/blood.V112.11.2522.2522

Published: 2008

Journal Articles

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

Blanca Espinet, PhD, Salaverría Itziar, PhD, Sílvia Beà, PhD, Neus Ruiz-Xivillé, Olga Balagué, MD, Marta Salido, Dolors Costa, PhD, Ana E Rodriguez, Juan LuíS. García, PhD, JesúS. M.ª Hernández-Rivas, MD, PhD, M.ª José Calasanz, PhD, Ana M Ferrer, MD, PhD, Antonio Salar, MD, PhD, Ana Carrió, PhD, Natividad Polo, Jose Antonio García-Marco, MD, PhD, Alicia Domingo, MD, Eva González-Barca, MD, PhD, Vicenç Romagosa, MD, Isabel Marugán, Armando López-Guillermo, MD, PhD, Fuensanta Millá, MD, José Luís Mate, MD, PhD, Elisa Luño, MD, PhD, Carmen Sanzo, MD, PhD, Rosa Collado, MD, PhD, Isabel Oliver, Sebastià Monzó, MD, Antonio Palacín, MD, Teresa González, Francesc Sant, MD, Ramon Salinas, MD, PhD, Mª Teresa Ardanaz, MD, Llorenç Font, MD, PhD, Lourdes Escoda, MD, Lourdes Florensa, MD, PhD, Elias Campo, MD, PhD, Sergi Serrano, MD, PhD, Francesc Solé, PhD

Blood (2008) 112 (11): 1765.

https://doi.org/10.1182/blood.V112.11.1765.1765

Published: 2008

Journal Articles

Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.

María Rozman, MD, Susana G. Kalko, PhD, Jordi Esteve, MD, Mireia Camós, MD, Josep-Lluís Aguilar, MD, Montserrat Torrebadell, MD, Dolors Costa, PhD, Ana Carrió, PhD, Pedro Jares, PhD, Emili Montserrat, MD, Elías Campo, MD

Blood (2006) 108 (11): 2244.

https://doi.org/10.1182/blood.V108.11.2244.2244

Published: 2006

NARROW

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.

Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.

Email alerts

ASH Publications

American Society of Hematology

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.

Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

Gene Expression Profiling of Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MD) Reveals a Biological Diversity Related to Underlying Cytogenetics but Also Identifies a Distinctive Profile in Normal Karyotype AML-MD.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only